Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Trial Details

NCT ID
NCT05945524
Phase
NA
Sponsor
University Hospital, Toulouse
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Bone marrow sampling
Locations (sample)
  • Amiens, France, France|49.9,2.3
  • Caen, France, France|49.18585,-0.35912
  • Dijon, France, France|47.31344,5.01391
  • Epagny Metz- Tessy, France, France
  • Lille, France, France|50.63391,3.05512

Key Eligibility Criteria

  • With multiple myeloma
  • Who receive Teclistamab
  • Consent form signed

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →